NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, Forecast & News

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ADIL shares have decreased by 11.1% and is now trading at $1.20. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adial Pharmaceuticals.

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Adial Pharmaceuticals.

2 brokers have issued 1 year price objectives for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Adial Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts' price targets for Adial Pharmaceuticals.

News coverage about ADIL stock has been trending very negative on Wednesday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAdial Pharmaceuticals.

Adial Pharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 40,900 shares, an increase of 42.0% from the February 27th total of 28,800 shares. Based on an average trading volume of 63,200 shares, the short-interest ratio is currently 0.6 days. Currently, 0.6% of the shares of the company are sold short. View Adial Pharmaceuticals' Current Options Chain.

Some companies that are related to Adial Pharmaceuticals include Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX), Alpine Immune Sciences (ALPN), Oramed Pharmaceuticals (ORMP), Processa Pharmaceuticals (PCSA), Catalyst Biosciences (CBIO), Enlivex Therapeutics (ENLV), Aridis Pharmaceuticals (ARDS), Oncolytics Biotech (ONCY), Vascular Biogenics (VBLT), VERONA PHARMA P/S (VRNA), Infinity Pharmaceuticals (INFI), Tiziana Life Sciences (TLSA), American Brivision (Holding) (ABVC) and Q BioMed (QBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Tandem Diabetes Care (TNDM), Altria Group (MO), Adobe (ADBE), Inovio Pharmaceuticals (INO), New Age Beverages (NBEV), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC) and Pfizer (PFE).

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADIL stock can currently be purchased for approximately $1.20.

Adial Pharmaceuticals has a market capitalization of $12.58 million. Adial Pharmaceuticals employs 3 workers across the globe. View additional information about Adial Pharmaceuticals.

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]